A Prospective Randomized Study of the Safety and Efficacy of Transforaminal Lumbar Interbody Fusion Versus Posterior Lumbar Interbody Fusion in the Treatment of Lumbar Spondylolisthesis: A Cost utility from a Lower-middle-income Country Perspective and Review of Literature

BACKGROUND: The safety and efficacy of transforaminal lumbar interbody fusion (TLIF) posterior (PLIF) in spondylolisthesis have not been validated many prospective randomized trials. AIM: We aimed to validate the TLIF PLIF surgery using clinical, radiographic, cost-utility outcomes. METHODS: data surgically treated single-level patients were prospectively into two groups. groups compared regarding demographics, perioperative complications, hospital stay, total expenditure, rate, clinical outcomes (visual analog scale, Oswestry disability index, Zurich claudication Odom’s criteria). A review literature was done compare with ones from higher-income nations. RESULTS: Thirty-three underwent randomization. improvement at 12-month follow-up showed group more than but no significant difference. mean operative time significantly longer (p < 0.05), also, blood loss less 0.001). complications frequency did show any statistical significance between both difference patient’s post-operative patient satisfaction = 0.6). stay non-significantly 0.7). At follow-up, 93.3% fused versus 86.7% 0.5). cost CONCLUSION: Both could achieve similar rates management spondylolisthesis. better terms financial burden, time, loss.